Lapatinib

摘要

HER2-targeted therapy has been shown to improve prognosis and quality of life in breast cancer patients. Lapatinib is a dual kinase inhibitor that inhibits both epidermal growth factor receptor and human epidermal receptor (HER) 2, and selectively suppresses cell growth of HER2-overexpressing breast cancer cells. This experimental finding has been confirmed in several clinical trials and lapatinib has been developed as a treatment option for HER2-positive tumours. #